Gitlab expects sales to slow this year and outlined several initiatives to help boost guidance that its chief executive officer described as disappointing. The provider of software development tools ...

GitLab (GTLB) is down 52.23% over the past year and 28.4% YTD at $26.87. Q4 revenue consensus of $257.3M exceeds guidance of $251-252M, with non-GAAP EPS expected at $0.2342. We will be updating this ...

GitLab (NASDAQ:GTLB) is gearing up to announce its quarterly earnings on Tuesday, 2026-03-03. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

Shoot ’em up game FZ: Formation Z will launch for PlayStation 5, Xbox Series, Switch 2, and PC via Steam and Epic Games Store on May 21, publisher and developer City Connection, and developer ...

Gitlab's results matched analyst estimates, but its growth rate slowed. Some investors seem to believe AI is more of a threat to the company than an opportunity. The stock is cheaper than it's ever ...

The platform warns users of on-premises versions to upgrade to the latest versions; SaaS and web versions have been patched. A critical two-factor authentication bypass vulnerability in the Community ...

The latest trends and issues around the use of open source software in the enterprise. The GitLab Duo Agent platform has reached general availability. This is an AI-native solution that embeds ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

GitLab is still a 'Buy,' as AI fears are overblown, with the stock trading at an inexplicably low valuation despite robust fundamentals. GTLB delivers 25% y/y revenue growth, beats Q3 estimates, and ...

Kilo Code makes a "vibe coding" extension for programming applications such as Microsoft's Visual Studio Code. The company was launched early this year by a group including Sid Sijbrandij, previously ...

Formation Bio is inking a deal worth more than $600 million in biobucks for ex-China rights to a next-gen immunology asset from Lynk Pharmaceuticals. Lynk’s program will be developed by Formation’s ...